SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

Strona główna・Stock List・Genfit

Genfit

Closed

SectorHealthcare

8.2 1.36

Buy Sell

Overview

Share price change

24h

Current

Min

8.2

Max

8.26

Key metrics
By Trading Economics
Income	-66M -76M
Sales	-3.6M 32M
Profit margin	-237.939
Employees	188
EBITDA	-8M -7M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+82.92% upside

Market Stats
By TradingEconomics
Market Cap	73M 446M
Previous open	6.84
Previous close	8.2

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

3.566 / 4.12 Support & Resistance

Genfit Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2026, 19:19 UTC

Acquisitions, Mergers, Takeovers

Intertek Group Rejects EQT's Revised Offer

24 kwi 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Scoring the Cook Era -- Barrons.com

24 kwi 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

24 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:09 UTC

Earnings

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 kwi 2026, 19:48 UTC

Market Talk

Major News Events

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 kwi 2026, 19:22 UTC

Earnings

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 kwi 2026, 19:06 UTC

Earnings

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 kwi 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 kwi 2026, 18:30 UTC

Acquisitions, Mergers, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 kwi 2026, 18:28 UTC

Acquisitions, Mergers, Takeovers

Intertek Rejects Revised EQT Offer

24 kwi 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 kwi 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 kwi 2026, 17:42 UTC

Earnings

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 kwi 2026, 17:28 UTC

Earnings

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 kwi 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 kwi 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 kwi 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 kwi 2026, 17:09 UTC

Market Talk

Earnings

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 kwi 2026, 17:09 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 17:06 UTC

Earnings

Acquisitions, Mergers, Takeovers

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 kwi 2026, 16:51 UTC

Earnings

Acquisitions, Mergers, Takeovers

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 kwi 2026, 16:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

24 kwi 2026, 16:20 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

24 kwi 2026, 16:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

24 kwi 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer Comparison

Price change

Genfit Forecast

Price Target

By TipRanks

82.92% upside

12 Months Forecast

Average 15 EUR 82.92%

High 15 EUR

Low 15 EUR

Based on 1 Wall Street analysts offering 12 month price targets forGenfit - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Genfit - Dist in the past 3 months.

Technical Score

By Trading Central

3.566 / 4.12Support & Resistance

Recent bullish events outweigh bearish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.